RxDoctor Payments Data

Firas Kaddaha, MD

Cardiovascular Disease · Farmville, VANPI 1003154337

Payments from drug & device makers

$3,352in general payments, 2019–2025

Across 71 payments — averaging $47.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$185
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$41
  • Novartis$36
  • Heartflow, Inc.$20
  • Johnson & Johnson$19
  • plus $43 from 3 others

What the payments were for

  • Travel & lodging$1,53246%
  • Food & beverage$1,82054%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,352 in reported general payments places this provider in the 60th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$157,422
Medicare patients
938
Services billed
1,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$167,435
EntrestoSacubitril/Valsartan82$70,763
XareltoRivaroxaban39$32,987
FarxigaDapagliflozin Propanediol49$31,031
Repatha SureclickEvolocumab24$22,408
JardianceEmpagliflozin22$12,969
Metoprolol Succinate367$3,946
Dabigatran EtexilateDabigatran Etexilate Mesylate14$3,187
Atorvastatin Calcium261$2,118
Torsemide61$1,089
Carvedilol200$1,013
Rosuvastatin Calcium79$986
Amlodipine Besylate168$747
Valsartan40$721
Lisinopril122$709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$36$70,76382 claims
Johnson & JohnsonXarelto$19$32,98739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Farmville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →